Roth Capital raised the firm's price target on CapsoVision to $11 from $7 and keeps a Buy rating on the shares after its Q4 pre-announcement and the closing of a $14M private placement. Proceeds from the financing are expected to support general corporate purposes, including R&D, sales and marketing, and working capital, with a focus on advancing key pipeline programs and AI capabilities, the analyst tells investors in a research note.
